Pneumonia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed that thearubigin caused a significant reduction in lung inflammation as evident from lung wet-to-dry weight ratio, BALF protein levels and MPO activity and histopathological analysis.
|
31832298 |
2019 |
Pneumonia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In an acute lung inflammation mouse model, an intratracheal (i.t.) eCS suppressed neutrophil infiltration, the expression of inflammatory cytokine genes, and MPO activity.In a sepsis mouse model, a single i.t. eCS was sufficient to significantly decrease mouse mortality.
|
30630473 |
2019 |
Pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Syzygium aromaticum aqueous extract inhibits human neutrophils myeloperoxidase and protects mice from LPS-induced lung inflammation.
|
30707845 |
2019 |
Pneumonia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Apremilast administration reduced lung inflammation in terms of reduction in myeloperoxidase activity and levels of tumor necrosis factor-alpha and alveolar infiltrating cells.
|
30500623 |
2019 |
Pneumonia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, FOM decreased MPO activity, pulmonary vascular permeability and edema formation in the lungs of mice with <i>S. aureus</i>-caused pneumonia.
|
31380296 |
2019 |
Pneumonia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our in vivo results demonstrated that Gln treatment reduced ET release (as indicated by cell-free-DNA content and myeloperoxidase activity), decreased lung inflammation (reductions in interferon-γ and increases in interleukin-10 levels), and improved lung morpho-function (decreased static lung elastance and alveolar collapse) in comparison with ARDS animals treated with saline.
|
31013737 |
2019 |
Pneumonia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, lestaurtinib pretreatment inhibited the aggregation and maturation of pulmonary cDCs, decreased lung MPO activity and T‑bet expression, and eventually improved LWW/BW, acute lung inflammation and injury.
|
31173158 |
2019 |
Pneumonia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment with rCHIPS reduces pulmonary inflammation and permeability in mice after intranasal administration of lipopolysaccharide (LPS). rCHIPS treatment significantly reduces lung myeloperoxidase (MPO) activity, pro-inflammatory cytokines, broncho-alveolar lavage (BAL) fluid protein content as well as histopathological changes.
|
30145330 |
2018 |
Pneumonia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reduction in the lung inflammation was associated with suppressed myeloperoxidase activity.
|
29355504 |
2018 |
Pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Concordantly, amplified accumulation of MPO leukocytes and significant pulmonary inflammation and pneumocyte apoptosis (TUNEL) was confirmed using qRT-PCR.
|
29118676 |
2017 |
Pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A single GLA exposure (1 mg/kg) induced seizures and inflammatory cell recruitment in the broncho-alveolar space, and increased myeloperoxidase (MPO), inducible NO synthase (iNOS), interstitial inflammation and disruption of alveolar septae within 6-24 h. Interleukin 1β (IL-1β) was increased and lung inflammation depended on IL-1 receptor 1 (IL-1R1).
|
27549113 |
2016 |
Pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that MPO catalysed formation of HOCl during lung inflammation should be considered as a significant source of neutrophil-induced genotoxicity.
|
19892774 |
2010 |
Pneumonia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of IL-8 and myeloperoxidase in the lungs of pneumonia patients.
|
11269653 |
2001 |